Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT01014208
What this trial is testing

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma

Who this might be right for
Lymphoma, Large-Cell, Diffuse
GlaxoSmithKline 447
Very early researchNot Yet RecruitingNCT07168291
What this trial is testing

Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Burkitt Lymphoma
First Affiliated Hospital Xi'an Jiaotong University 3
Testing effectiveness (Phase 2)Study completedNCT00452374
What this trial is testing

Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 48
Testing effectiveness (Phase 2)WithdrawnNCT04285268
What this trial is testing

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
High Grade B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell Lymphoma+4 more
Rutgers, The State University of New Jersey
Testing effectiveness (Phase 2)Study completedNCT02399085
What this trial is testing

Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL

Who this might be right for
Diffuse Large B-cell Lymphoma
MorphoSys AG 81
Testing effectiveness (Phase 2)Study completedNCT01076543
What this trial is testing

Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Who this might be right for
AIDS-Related Hodgkin LymphomaRecurrent Adult Hodgkin LymphomaRecurrent Follicular Lymphoma+5 more
National Cancer Institute (NCI) 110
Early research (Phase 1)Not Yet RecruitingNCT07725406
What this trial is testing

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

Who this might be right for
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed or Refractory Multiple Myeloma (MM)
Weill Medical College of Cornell University 32
Testing effectiveness (Phase 2)Looking for participantsNCT04186520
What this trial is testing

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Who this might be right for
Non Hodgkin Lymphoma (NHL)Mantle Cell Lymphoma (MCL)Chronic Lymphocytic Leukemia (CLL)+5 more
Medical College of Wisconsin 100
Large-scale testing (Phase 3)WithdrawnNCT06205290
What this trial is testing

Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Who this might be right for
Leukemia, Lymphocytic, Chronic, B-Cell
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Very early researchUnknownNCT05739227
What this trial is testing

Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies

Who this might be right for
Acute Lymphoblastic LeukemiaB-cell LymphomaChronic Lymphocytic Leukemia
Xuzhou Medical University 12
Testing effectiveness (Phase 2)Ended earlyNCT05179603
What this trial is testing

SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]

Who this might be right for
Classic Hodgkin LymphomaDiffuse Large B-cell Lymphoma
Sanofi 14
Large-scale testing (Phase 3)Study completedNCT00003687
What this trial is testing

Treatment for Chronic Pain in Patients With Advanced Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+6 more
NCIC Clinical Trials Group 87
Testing effectiveness (Phase 2)WithdrawnNCT00310128
What this trial is testing

Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

Who this might be right for
AIDS-related LymphomaAdult Non-Hodgkin's LymphomaAnaplastic Large Cell Lymphoma
AIDS Malignancy Consortium
Testing effectiveness (Phase 2)Ended earlyNCT00012298
What this trial is testing

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Grade 1 Follicular Lymphoma+6 more
National Cancer Institute (NCI) 81
Testing effectiveness (Phase 2)Ended earlyNCT00005852
What this trial is testing

Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+3 more
H. Lee Moffitt Cancer Center and Research Institute
Not applicableUnknownNCT06497452
What this trial is testing

Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

Who this might be right for
B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University 50
Early research (Phase 1)Ended earlyNCT06248086
What this trial is testing

Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas

Who this might be right for
B-cell Lymphoma
Astellas Pharma Global Development, Inc. 1
Large-scale testing (Phase 3)Ended earlyNCT04236141
What this trial is testing

Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).

Who this might be right for
Diffuse, Large B-Cell, Lymphoma
Hoffmann-La Roche 42
Testing effectiveness (Phase 2)Study completedNCT00006473
What this trial is testing

Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Angioimmunoblastic T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell Lymphoma+14 more
National Cancer Institute (NCI) 72
Large-scale testing (Phase 3)Ended earlyNCT01232556
What this trial is testing

Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Who this might be right for
Lymphoma, Non-Hodgkin
Pfizer 338
Next Page